uniQure (NASDAQ:QURE) Price Target Lowered to $25.00 at Barclays

uniQure (NASDAQ:QURE) had its target price decreased by Barclays from $31.00 to $25.00 in a report released on Monday morning,Benzinga reports. Barclays currently has an equal weight rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on QURE. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. The Goldman Sachs Group lowered their price objective on uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, Leerink Partners reissued an “outperform” rating and set a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.75.

uniQure Trading Down 1.1%

uniQure stock opened at $15.92 on Monday. The firm has a 50 day moving average of $20.45 and a 200 day moving average of $29.63. The firm has a market capitalization of $995.48 million, a price-to-earnings ratio of -4.61 and a beta of 0.73. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, research analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently bought and sold shares of QURE. Swiss National Bank bought a new stake in uniQure during the second quarter worth approximately $1,080,000. Sanders Morris Harris LLC purchased a new stake in uniQure during the third quarter valued at approximately $5,081,000. Vanguard Group Inc. lifted its stake in shares of uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares during the last quarter. Aberdeen Group plc raised its holdings in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after buying an additional 189,029 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after buying an additional 1,491,486 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.